Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

HER2 Circulating Tumor Cells in Gastric Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2013 by Samsung Medical Center.
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Won Ki Kang, Samsung Medical Center Identifier:
First received: February 17, 2011
Last updated: June 12, 2013
Last verified: June 2013
The investigators propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer.

Gastric Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: HER2 Circulating Tumor Cells in Gastric Cancer

Resource links provided by NLM:

Further study details as provided by Samsung Medical Center:

Primary Outcome Measures:
  • To survey the frequency of HER2(+) CTC in gastric cancer [ Time Frame: 24month ]

Biospecimen Retention:   Samples Without DNA
blood, circulating tumor cell

Estimated Enrollment: 200
Study Start Date: March 2010
Estimated Study Completion Date: September 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Detailed Description:
We propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer. Blood samples will be collected from metastatic gastric cancer patients.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
metastatic gastric cancer

Inclusion Criteria:

  • Patients older than 18 years ② Patients with localized, histologically confirmed gastric cancer ③ Informed consent form

Exclusion Criteria:

  • No informed consent form
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01299688

Korea, Republic of
Samsung Medical Center
Seoul, Korea, Republic of
Sponsors and Collaborators
Samsung Medical Center
Principal Investigator: Won Ki Kang, MD Samsung Medical Center
  More Information

Responsible Party: Won Ki Kang, Professor, Samsung Medical Center Identifier: NCT01299688     History of Changes
Other Study ID Numbers: 2009-12-008
Study First Received: February 17, 2011
Last Updated: June 12, 2013

Additional relevant MeSH terms:
Stomach Neoplasms
Neoplastic Cells, Circulating
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes processed this record on May 22, 2017